



LTC Newsletter 2021-47 Sept. 24, 2021

LTC Update:

- Vaccine Booster Dose Pfizer
- CDC Guidance on Eye Protection
- Monoclonal Antibody Request Deadline
- New CMS & CDC Guidance Documents

Vaccine Booster Dose – Pfizer

The CDC has issued Pfizer booster eligibility guidance. Long-term care residents that received the Pfizer vaccine as their primary series and there has been at least six months from the second dose are eligible for the booster. Please identify any resident who is eligible and offer them the booster. If a facility is unable to obtain Pfizer vaccine for the booster from their pharmacy partner, please contact Probari at outreach@probarisystems.com or 317-804-4102.

Pfizer COVID-19 Booster Dose Information

CDC Guidance on Eye Protection

During substantial to high transmission, eye protection (i.e., goggles or a face shield that covers the front and sides of the face) should be worn during all resident care encounters. This is an important change from our currently published SOP.

The current SOP is being updated to include this information and will be released next week.

Facilities needing assistance obtaining eye protection for staff, only face shields are available to be ordered through Langham.

Information for ordering supplies: Instructions and Order Form

Monoclonal Antibody Request – Deadline

Long-term care facilities and pharmacies with the capability to administer monoclonal antibody therapy (MAB) and have signed up for the distribution list to request allocations should refer to the weekly email for the updated deadline to submit requests.

Please see <u>LTC Newsletter 2021-46</u> – Monoclonal Antibody (MAB) therapy for confirmed COVID-19 and for post-exposure prophylaxis in COVID-19.

New CMS & CDC Guidance Documents

IDOH COVID-19 Long-term Care SOP is currently being updated to reflect the new guidance from the CMS and CDC.

QSO-20-38-NH REVISED | CMS - Revised 09/10/2021

<u>Interim Infection Prevention and Control Recommendations to Prevent SARS-CoV-2 Spread in Nursing Homes | CDC</u> – Updated 09/10/2021

<u>Infection Control: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | CDC</u> – Updated 9/10/2021

<u>Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 | CDC</u> – Updated 9/10/2021